340 related articles for article (PubMed ID: 22037104)
1. From whole blood to component therapy: the economic, supply/demand need for implementation of component therapy in sub-Saharan Africa.
Erhabor O; Adias TC
Transfus Clin Biol; 2011 Dec; 18(5-6):516-26. PubMed ID: 22037104
[TBL] [Abstract][Full Text] [Related]
2. New technologies for the inactivation of infectious pathogens in cellular blood components and the development of platelet substitutes.
Corash L
Baillieres Best Pract Res Clin Haematol; 2000 Dec; 13(4):549-63. PubMed ID: 11102276
[TBL] [Abstract][Full Text] [Related]
3. Reducing replacement donors in Sub-Saharan Africa: challenges and affordability.
Bates I; Manyasi G; Medina Lara A
Transfus Med; 2007 Dec; 17(6):434-42. PubMed ID: 18067647
[TBL] [Abstract][Full Text] [Related]
4. Transfusion-transmitted malaria in countries where malaria is endemic: a review of the literature from sub-Saharan Africa.
Owusu-Ofori AK; Parry C; Bates I
Clin Infect Dis; 2010 Nov; 51(10):1192-8. PubMed ID: 20929356
[TBL] [Abstract][Full Text] [Related]
5. Biologic effects of leukocytes present in transfused cellular blood products.
Bordin JO; Heddle NM; Blajchman MA
Blood; 1994 Sep; 84(6):1703-21. PubMed ID: 8080981
[TBL] [Abstract][Full Text] [Related]
6. Should we neglect or nurture replacement blood donors in sub-Saharan Africa?
Bates I; Hassall O
Biologicals; 2010 Jan; 38(1):65-7. PubMed ID: 20089417
[TBL] [Abstract][Full Text] [Related]
7. The use of leukocyte-reduced blood components.
Miller JP; Mintz PD
Hematol Oncol Clin North Am; 1995 Feb; 9(1):69-90. PubMed ID: 7737945
[TBL] [Abstract][Full Text] [Related]
8. Current good manufacturing practices for blood and blood components: notification of consignees receiving blood and blood components at increased risk for transmitting HIV infection--FDA. Final rule.
Fed Regist; 1996 Sep; 61(175):47413-23. PubMed ID: 10160337
[TBL] [Abstract][Full Text] [Related]
9. Advances in transfusion therapy.
Beck SJ
Clin Lab Sci; 1994; 7(4):225-31. PubMed ID: 10147432
[TBL] [Abstract][Full Text] [Related]
10. Warm fresh whole blood transfusion for severe hemorrhage: U.S. military and potential civilian applications.
Spinella PC
Crit Care Med; 2008 Jul; 36(7 Suppl):S340-5. PubMed ID: 18594261
[TBL] [Abstract][Full Text] [Related]
11. Blood component use in a sub-Saharan African country: results of a 4-year evaluation of diagnoses associated with transfusion orders in Namibia.
Pitman JP; Wilkinson R; Liu Y; von Finckenstein B; Smit Sibinga CT; Lowrance DW; Marfin AA; Postma MJ; Mataranyika M; Basavaraju SV
Transfus Med Rev; 2015 Jan; 29(1):45-51. PubMed ID: 25573416
[TBL] [Abstract][Full Text] [Related]
12. Leukocyte depletion of cellular blood components.
Lane TA
Curr Opin Hematol; 1994 Nov; 1(6):443-51. PubMed ID: 9371321
[TBL] [Abstract][Full Text] [Related]
13. Effect of pathogen inactivation on the storage lesion in red cells and platelet concentrates.
Seghatchian J; Hervig T; Putter JS
Transfus Apher Sci; 2011 Aug; 45(1):75-84. PubMed ID: 21782517
[TBL] [Abstract][Full Text] [Related]
14. Leukocyte-reduced blood components: patient benefits and practical applications.
Higgins VL
Oncol Nurs Forum; 1996 May; 23(4):659-67. PubMed ID: 8735324
[TBL] [Abstract][Full Text] [Related]
15. Pathogen-reduction systems for blood components: the current position and future trends.
Seghatchian J; de Sousa G
Transfus Apher Sci; 2006 Dec; 35(3):189-96. PubMed ID: 17110168
[TBL] [Abstract][Full Text] [Related]
16. From leukocyte reduction to leukocyte transfusion: the immunological effects of transfused leukocytes.
Lee JH; Klein HG
Baillieres Best Pract Res Clin Haematol; 2000 Dec; 13(4):585-600. PubMed ID: 11102278
[TBL] [Abstract][Full Text] [Related]
17. Algorithmic and consultative integration of transfusion medicine and coagulation: a personalized medicine approach with reduced blood component utilization.
Brown RE; Dorion RP; Trowbridge C; Stammers AH; Fitt W; Davis J
Ann Clin Lab Sci; 2011; 41(3):211-6. PubMed ID: 22075502
[TBL] [Abstract][Full Text] [Related]
18. Use of platelets and other transfusion products in patients with malignancy.
Bayer WL; Bodensteiner DC; Tilzer LL; Adams ME
Semin Thromb Hemost; 1992; 18(4):380-91. PubMed ID: 1470926
[TBL] [Abstract][Full Text] [Related]
19. Non-infectious complications of transfusion therapy.
Perrotta PL; Snyder EL
Blood Rev; 2001 Jun; 15(2):69-83. PubMed ID: 11409907
[TBL] [Abstract][Full Text] [Related]
20. Plasma exchange donation of cryoprecipitate after DDAVP stimulation: an alternative source of factor VIII.
McLeod BC; Scott JP
Prog Clin Biol Res; 1990; 324():189-98. PubMed ID: 2106687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
